Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines

Imatinib mesylate (IM) is a tyrosine kinase inhibitor, which inhibits phosphorylation of downstream proteins involved in BCR-ABL signal transduction. It has proved beneficial in treating patients with chronic myeloid leukaemia (CML). In addition, IM demonstrates activity against malignant cells expr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Uziel, O, Fenig, E, Nordenberg, J, Beery, E, Reshef, H, Sandbank, J, Birenbaum, M, Bakhanashvili, M, Yerushalmi, R, Luria, D, Lahav, M
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2005
Teme:
Translational Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361771/
https://ncbi.nlm.nih.gov/pubmed/15870711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602592
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items